JEFFREY ZIGMAN, MD PhD
5323 HARRY HINES BLVD · Dallas, TX 75390
Total Wellness and Bariatrics (formerly McCarty Weight Loss Center) · 9440 Poppy Drive · Dallas, TX 75218
4.5· 71 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Total Wellness and Bariatrics, formerly McCarty Weight Loss Center, is a weight-loss center in Dallas, Texas, offering both non-surgical weight-loss plans and weight-loss surgery according to its website. The site describes consultations as conversations in which the team listens before advising on a procedure, and it mentions a Mini Sleeve gastric sleeve procedure and medically supervised non-surgical programs. On Google it holds a 4.5-star rating across 71 reviews dating back to 2013, with 24 in the past year. Reviewers most often mention the staff, with 37 reviews, and results, with 24.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-24. Read the reviews themselves on the practice's Google listing.
Rated ★4.5 across 71 Google reviews. Of the 71 reviews we analyzed, 60 (85%) are positive (4–5★) and 7 (10%) are negative (1–2★).
Frances L.★★★★★2026-09-24Always respond quickly when I have questions. Wonderful bedside manners
Reda F.★★★★★2026-09-17I have met with two Surgeons during this journey and I will say that after today, I left my consultation feeling confident, no longer nervous and overall just completely confident that this mini sleeve procedure will be for the better for my family and I! I owe it all to Dr K.
MariaChristina B.★★★★★2026-09-09I had a wonderful experience with Dr. Ikram Kureshi. He took the time to listen to all of my questions and concerns and explained everything in a way that made me feel comfortable and reassured. His knowledge, professionalism, and caring approach immediately put me at ease. I left my appointment feeling confident and very pleased with my care. I highly recommend Dr. Kureshi!
Lea M.★★★★★2026-08-22From the front staff, to behind the scenes this is by far the best healthcare and consistent customer service in the DFW area. No appointment ever feels rushed and every concern & question is always fully answered. I am beyond grateful to the entire staff for making my important life choices such an amazing experience.
Cathy C.★★★★★2026-08-19Dr. Kureshi and everyone on his staff are very nice and always ready to answer any questions I might have. Doctor is very patient during review calls and doesn't rush the call or ignore any concerns you might have.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
5323 HARRY HINES BLVD · Dallas, TX 75390
12200 PARK CENTRAL DR STE 200 · Dallas, TX 75251
5323 HARRY HINES BLVD · Dallas, TX 75390
2001 INWOOD RD · Dallas, TX 75390
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs